IP Library Granted Patent US 11,472,831
Granted Patent B2
US 11,472,831 · App. 16/632,093 · Granted Oct 18, 2022

Isotopically labeled bile acid derivatives

Inventors: Gabriel Galvin (San Diego, CA); Kevin Schaab (San Diego, CA); Mathew Yanik (San Diego, CA)
Assignee: Intercept Pharmaceuticals, Inc.
C07J41/0061C07J9/005C07J17/005C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,472,831
App. No.
16/632,093
Granted
Oct 18, 2022
Kind
B2
Abstract

The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof.

Claims (27)

1. A compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein

R 1 is OH, glucuronide, OSO 3 H, SO 3 H, C(O)R 6 , or 14 C(O)R 6 ;

R 2 is hydrogen, deuterium, or OH;

R 3 is OH or glucuronide;

R 4 is OH or glucuronide;

R 6 is NH(CH 2 ) 2 SO 3 H, NHCH 2 CO 2 H, or N(CH 3 )CH 2 CO 2 H or glucuronide, wherein the hydrogen atoms in R 6 can be replaced with deuterium;

R 11 is Z 11b , hydroxy, halogen, or alkoxy, or oxo when Z 11a is not present;

R 16 is Z 16a , hydroxy, halogen, or alkoxy, or oxo when Z 16b is not present;

R 23 is Z 23a or alkyl; and

Z 1a , Z 1b , Z 2a , Z 2b , Z 3 , Z 4a , Z 4b , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 11a , Z 11b , Z 12 , Z 14 , Z 15a , Z 15b , Z 16a , Z 16b , Z 17 , Z 18 , Z 19 , Z 20 , Z 21 , Z 22a , Z 22b , Z 23a , Z 23b , Z 24a , Z 24b , or Z 25 is independently hydrogen or deuterium, and at least one of Z 1a , Z 1b , Z 2a , Z 2b , Z 3 , Z 4a , Z 4b , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 11a , Z 11b , Z 12 , Z 14 , Z 15a , Z 15b , Z 16a , Z 16b , Z 17 , Z 18 , Z 19 , Z 20 , Z 21 , Z 22a , Z 22b , Z 23a , Z 23b , Z 24a , Z 24b , or Z 25 is deuterium; and

any carbon atom is 12 C, 13 C, or 14 C.

2. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula II

3. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula III

4. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula IV

5. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula V

6. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula VI

7. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula VII

8. The compound of claim 1 , wherein the compound of Formula I is a compound of Formula VIII

wherein R 1 is 14 C(O)R 6 .

9. The compound of claim 1 , wherein R 2 is hydrogen.

10. The compound of claim 1 , wherein the compound is selected from

11. The compound of claim 1 , wherein R 1 is C(O)R 6 .

12. The compound of claim 1 , wherein R 1 is 14 C(O)R 6 .

13. The compound of claim 1 , wherein R 6 is NH(CH 2 ) 2 SO 3 H, NHCH 2 CO 2 H, or N(CH 3 )CH 2 CO 2 H.

14. The compound of claim 1 , wherein R 3 is glucuronide.

15. The compound of claim 1 , wherein the compound is

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0990 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2020
From: GALVIN, GABRIEL; SCHAAB, KEVIN; YANIK, MATHEW
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 052326/0409 →
Continuity (3)
Provisional Application 62536609 · Jul 25, 2017
Provisional Application 62536326 · Jul 24, 2017
Related Publication 20200165290A1 · May 28, 2020